Gland Pharma reports nearly 50% jump in Q1 profit

Published On 2025-08-07 04:30 GMT   |   Update On 2025-08-07 04:30 GMT
Advertisement

Hyderabad-based Gland Pharma has posted a nearly 50 percent surge in first-quarter profit, driven by improved margins and a recovery at its European unit Cenexi.

The company reported a consolidated net profit of Rs 2.15 billion (approximately $24.5 million) for the quarter ended June 30, up from Rs 1.44 billion in the same period last year.

Revenue from operations rose 7.4% to 15.06 billion rupees. While sales from its U.S. business, which accounts for nearly half of the total, fell 2%, its Europe business posted a 29% rise.

Gland and several Indian pharma companies that make generic drugs derive a significant share of revenue from the United States and has continued to face pricing pressure in that market following U.S. President Donald Trump's imposition of hefty tariffs on goods imported from India, Reuters reported.
Read also: Gland Pharma Visakhapatnam facility gets USFDA EIR
Rivals Sun Pharma, and Cipla, and Dr Reddy's
Advertisement
, reported subdued U.S. sales in the quarter.
However, Gland Pharma said improved margins and Cenexi's earnings before interest, taxes, depreciation, and amortisation (EBITDA) break-even supported quarterly performance, marking a turnaround after production setbacks at its Paris and Belgium units weighed on earnings over the past year.
The company’s EBITDA margin rose to 35% in the June quarter from 29% a year earlier.
Read also: Gland Pharma Pashamylaram facility receives GMP compliance certificate from Danish Medicines Agency
Tags:    
Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News